Many signaling pathways that are mutated in human cancer are evolutionarily conserved. Genetic studies of these pathways in model organisms may yield insights into cancer pathogenesis. The candidate is an M.D.-Ph.D. with a strong background in signal transduction research. He has recently completed a medical oncology fellowship and seeks to establish a career as an independent physician-scientist by using C. elegans as a genetic model system to study evolutionarily conserved signaling pathways that are deranged in cancer. As proof of principle, he proposes to identify and characterize novel components of the C. elegans DAF-18/PTEN signaling pathway in the laboratory of Dr. Gary Ruvkun at MGH. The PTEN tumor suppressor is mutated in a wide variety of cancers. It antagonizes an oncogenic PI3-kinase/Akt signaling cascade by virtue of its 3-phosphoinositide phosphatase activity, preventing Akt kinase activation. Detailed molecular analysis of this pathway is critical to an improved understanding of tumorigenesis and the development of new treatments for diverse human cancers. Genetic analysis has identified six components of the DAF-18/PTEN signaling cascade in C. elegans, all of which are conserved in humans. Five of these molecules have been implicated in oncogenesis. This striking conservation indicates that insights gained from studying DAF-18/PTEN signaling in C. elegans will impact upon our understanding of cancer pathogenesis in humans. The research proposal is a multifaceted approach focused on the identification and characterization of novel components of DAF-18/PTEN signaling. It includes forward genetic, functional genomic, and RNAi-based strategies. By taking full advantage of the genetic tractability of C. elegans, the well- annotated and complete genome sequence, and the recent adaptation of RNAi to h i gh-throughput analysis, this approach should greatly accelerate our understanding of DAF-18/PTEN signaling.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Hyde, James F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Alam, Hena; Williams, Travis W; Dumas, Kathleen J et al. (2010) EAK-7 controls development and life span by regulating nuclear DAF-16/FoxO activity. Cell Metab 12:30-41
Dumas, Kathleen J; Guo, Chunfang; Wang, Xi et al. (2010) Functional divergence of dafachronic acid pathways in the control of C. elegans development and lifespan. Dev Biol 340:605-12
Zhang, Yanmei; Xu, Jinling; Puscau, Cristina et al. (2008) Caenorhabditis elegans EAK-3 inhibits dauer arrest via nonautonomous regulation of nuclear DAF-16/FoxO activity. Dev Biol 315:290-302
Hu, Patrick J (2007) Dauer. WormBook :1-19
Hu, Patrick J; Xu, Jinling; Ruvkun, Gary (2006) Two membrane-associated tyrosine phosphatase homologs potentiate C. elegans AKT-1/PKB signaling. PLoS Genet 2:e99
Tewari, Muneesh; Hu, Patrick J; Ahn, Jin Sook et al. (2004) Systematic interactome mapping and genetic perturbation analysis of a C. elegans TGF-beta signaling network. Mol Cell 13:469-82